AppointmentsPharming changes CEO, Evotec loses CSO and Nanobiotix hires CFOEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: an immediate CEO change at Pharming, … more ➔
clinical dataAmplio’s Phase 1b data hint at better first-line arthritis treatmentAmsterdam-based Amplio Pharma has reported early clinical evidence that its experimental treatment NovoBioJect boosts the active form of methotrexate inside immune cells. The company is seeking about … more ➔
licensingGSK adds liver candidate from Wave RNA partnershipGSK has selected a liver disease drug candidate from its collaboration with Wave Life Sciences for further development, triggering a $12 million (€11 million) milestone payment to the U.S.-based b … more ➔
clinical dataHighlight Therapeutics’ skin cancer injections show promise in Phase 2bSpain’s Highlight Therapeutics reported that its lead candidate, BO-112, met its Phase 2b endpoint in localized basal cell carcinoma, with 61% of evaluable patients achieving a response. more ➔
clinical dataBoehringer, Zealand obesity drug face tolerability questions after Phase 3 successBoehringer Ingelheim’s survodutide delivered average weight loss of up to 13.1% in a Phase 3 trial involving people with overweight or obesity and type 2 diabetes, but gastrointestinal side effects … more ➔
licensingSanofi pays $1B upfront to expand Regeneron alliance beyond DupixentSanofi will pay Regeneron Pharmaceuticals $1 billion upfront (€0.9 billion) to expand the alliance that led to the blockbuster Dupixent with four antibody candidates designed to work longer between … more ➔
clinical dataAtrogi’s muscle drug shows early power signal ahead of Phase 2Swedish biotech Atrogi says its oral drug ATR-258 increased lower-extremity muscle power by about 13% after eight weeks in a study of 13 people with overweight or obesity. Participants also lost an average … more ➔
multiple sclerosisImmunic CEO: “We want to understand MS patients better than anyone”Immunic is preparing to transition from a late-stage development biotechnology company into a fully integrated commercial organization focused on multiple sclerosis (MS). At the center of its strategy … more ➔
licensingAstraZeneca boards the PD-1/VEGF ship with $2B Summit investmentAstraZeneca has agreed to invest $2 billion (€1.8 billion) in Summit Therapeutics and test its cancer drug ivonescimab alongside the British pharma’s antibody-drug conjugates. more ➔
clinical datauniQure falls as Huntington’s gene therapy shows mixed resultsuniQure’s shares fell about 40% in early trading on September 29 after its Huntington’s gene therapy missed statistical significance on the main disease progression measure after four years. The … more ➔
